JP2023551355A5 - - Google Patents
Info
- Publication number
- JP2023551355A5 JP2023551355A5 JP2023520181A JP2023520181A JP2023551355A5 JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5 JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023520181 A JP2023520181 A JP 2023520181A JP 2023551355 A5 JP2023551355 A5 JP 2023551355A5
- Authority
- JP
- Japan
- Prior art keywords
- here
- group
- ring
- independently
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011061580 | 2020-09-30 | ||
| CN202011061580.7 | 2020-09-30 | ||
| PCT/CN2021/121721 WO2022068878A1 (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551355A JP2023551355A (ja) | 2023-12-08 |
| JP2023551355A5 true JP2023551355A5 (cg-RX-API-DMAC7.html) | 2024-10-08 |
Family
ID=80951198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520181A Pending JP2023551355A (ja) | 2020-09-30 | 2021-09-29 | 抗腫瘍化合物並びにその調製方法及び使用 |
Country Status (21)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4516357T3 (da) * | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| AU2022269073A1 (en) | 2021-05-07 | 2023-11-23 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
| CN115557962A (zh) * | 2021-07-02 | 2023-01-03 | 石药集团巨石生物制药有限公司 | 新型喜树碱类化合物及其制备方法和应用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CA3224492A1 (en) | 2021-07-19 | 2023-01-26 | Xiaojun Han | Immunoconjugates and methods |
| CN115850291B (zh) * | 2021-09-24 | 2024-11-15 | 石药集团巨石生物制药有限公司 | 喜树碱衍生物及其用途 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN118829450A (zh) * | 2022-01-18 | 2024-10-22 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
| EP4470570A1 (en) * | 2022-01-28 | 2024-12-04 | Duality Biologics (Suzhou) Co., Ltd. | Her3 antibody-drug conjugate and use thereof |
| JP2025509286A (ja) * | 2022-03-10 | 2025-04-11 | ビバソル, インコーポレイテッド | 抗体-薬物コンジュゲートおよびその使用 |
| US20250195681A1 (en) * | 2022-03-18 | 2025-06-19 | Duality Biologics (Suzhou) Co., Ltd. | Anti-gpc3 antibody drug conjugate and use thereof |
| TW202344252A (zh) * | 2022-05-09 | 2023-11-16 | 大陸商同宜醫藥(蘇州)有限公司 | 一種喜樹鹼衍生物,基於其的抗體-藥物偶聯物和藥物組成物,及其應用 |
| JP2025515988A (ja) * | 2022-05-13 | 2025-05-23 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| AU2023282410A1 (en) * | 2022-06-07 | 2024-12-05 | Duality Biologics (Suzhou) Co., Ltd. | Anti-b7h3 antibody-drug conjugate and use thereof |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| CN117024438B (zh) * | 2022-07-29 | 2026-05-05 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| CN120225528A (zh) | 2022-09-02 | 2025-06-27 | 默沙东有限责任公司 | 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途 |
| AU2023349279A1 (en) * | 2022-09-30 | 2025-05-15 | Beone Medicines I Gmbh | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| KR20250079227A (ko) | 2022-10-25 | 2025-06-04 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도 |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| CN119855820A (zh) * | 2022-12-16 | 2025-04-18 | 上海齐鲁制药研究中心有限公司 | 喜树碱类化合物及其制备方法和用途 |
| KR20250128359A (ko) * | 2022-12-27 | 2025-08-27 | 듀얼리티 바이올로직스 (상하이) 컴퍼니 리미티드 | 항 b7h3 및 pd-l1의 이중특이성 항체-약물 접합체 및 이의 제조 방법과 용도 |
| NZ821249A (en) * | 2022-12-28 | 2026-03-27 | Adcendo Aps | Antibody-drug conjugates targeting uparap comprising exatecan derivatives |
| CN116712561A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | 含n-亚甲基酰胺连接子的抗体-药物偶联物 |
| CN122080121A (zh) | 2023-03-22 | 2026-05-26 | 映恩生物科技(上海)有限公司 | 连接子及其在配体药物偶联物中的应用 |
| CN121038817A (zh) | 2023-04-10 | 2025-11-28 | 第一三共株式会社 | 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| CN120958033B (zh) * | 2023-08-04 | 2026-03-31 | 映恩生物制药(苏州)有限公司 | 抗体药物偶联物的识别抗体及其应用 |
| WO2025166725A1 (en) | 2024-02-08 | 2025-08-14 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| WO2025056748A1 (en) | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| WO2025054996A1 (en) | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| TW202540115A (zh) | 2023-11-16 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 一種氘代喜樹鹼化合物及其製備和應用 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗il-1rap結合結構域及其抗體-藥物偶聯物 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| TW202612739A (zh) | 2024-05-16 | 2026-04-01 | 日商第一三共股份有限公司 | 抗b7-h3抗體-藥物結合物與雄性素受體傳訊抑制劑之組合 |
| WO2025247255A1 (zh) * | 2024-05-28 | 2025-12-04 | 映恩生物科技(上海)有限公司 | 一种抗dll3抗体、抗体药物偶联物及其应用 |
| TW202613129A (zh) * | 2024-05-31 | 2026-04-01 | 大陸商杭州中美華東製藥有限公司 | 一種喜樹鹼類化合物及其應用 |
| CN122497675A (zh) * | 2024-06-05 | 2026-07-31 | 荣昌生物制药(烟台)股份有限公司 | 一种喜树碱类化合物及其用途 |
| EP4766727A1 (en) | 2024-06-14 | 2026-07-01 | Biontech SE | Polytherapy for the treatment of cancer |
| WO2025256761A1 (en) | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| WO1999061061A1 (fr) * | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| SG11201603960XA (en) * | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| US11185594B2 (en) * | 2014-04-10 | 2021-11-30 | Daiichi Sankyo Company, Limited | (Anti-HER2 antibody)-drug conjugate |
| WO2018066626A1 (ja) * | 2016-10-07 | 2018-04-12 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート投与による耐性癌の治療 |
| CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN110016026B (zh) * | 2018-01-08 | 2022-11-25 | 上海凌济生物科技有限公司 | 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途 |
| UA130338C2 (uk) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| JP7408646B2 (ja) * | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗-b7h3抗体-エキサテカンアナログコンジュゲート及びその医薬用途 |
| EP3876998A1 (en) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| DK4516357T3 (da) * | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| WO2022078279A1 (zh) | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| EP4227310A4 (en) | 2020-10-12 | 2024-11-06 | Sichuan Baili Pharmaceutical Co. Ltd. | CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF |
| CN114569739A (zh) | 2020-12-01 | 2022-06-03 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
| AU2022216696A1 (en) | 2021-02-05 | 2023-08-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| AU2022269073A1 (en) | 2021-05-07 | 2023-11-23 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
-
2021
- 2021-09-29 DK DK24204055.8T patent/DK4516357T3/da active
- 2021-09-29 LT LTEP24204055.8T patent/LT4516357T/lt unknown
- 2021-09-29 CN CN202610026243.5A patent/CN122005840A/zh active Pending
- 2021-09-29 JP JP2023520181A patent/JP2023551355A/ja active Pending
- 2021-09-29 CN CN202610026440.7A patent/CN122005841A/zh active Pending
- 2021-09-29 PL PL24204055.8T patent/PL4516357T3/pl unknown
- 2021-09-29 EP EP24204055.8A patent/EP4516357B1/en active Active
- 2021-09-29 IL IL301793A patent/IL301793A/en unknown
- 2021-09-29 CN CN202211403184.7A patent/CN116199739B/zh active Active
- 2021-09-29 FI FIEP24204055.8T patent/FI4516357T3/fi active
- 2021-09-29 PT PT242040558T patent/PT4516357T/pt unknown
- 2021-09-29 CN CN202180018263.3A patent/CN115175705B/zh active Active
- 2021-09-29 TW TW110136259A patent/TW202214230A/zh unknown
- 2021-09-29 CN CN202610025967.8A patent/CN121944137A/zh active Pending
- 2021-09-29 CN CN202211407530.9A patent/CN115925796B/zh active Active
- 2021-09-29 MX MX2023003778A patent/MX2023003778A/es unknown
- 2021-09-29 HR HRP20260401TT patent/HRP20260401T1/hr unknown
- 2021-09-29 SM SM20260197T patent/SMT202600197T1/it unknown
- 2021-09-29 KR KR1020237011470A patent/KR20230079085A/ko active Pending
- 2021-09-29 RS RS20260508A patent/RS68033B1/sr unknown
- 2021-09-29 ES ES24204055T patent/ES3067785T3/es active Active
- 2021-09-29 CN CN202310152789.1A patent/CN116239601B/zh active Active
- 2021-09-29 AU AU2021354823A patent/AU2021354823A1/en active Pending
- 2021-09-29 EP EP21874533.9A patent/EP4223318A4/en active Pending
- 2021-09-29 CN CN202610025121.4A patent/CN121987815A/zh active Pending
- 2021-09-29 CA CA3195515A patent/CA3195515A1/en active Pending
- 2021-09-29 WO PCT/CN2021/121721 patent/WO2022068878A1/zh not_active Ceased
- 2021-09-29 SI SI202130420T patent/SI4516357T1/sl unknown
-
2022
- 2022-05-26 US US17/825,090 patent/US11685742B2/en active Active
- 2022-05-31 US US17/828,433 patent/US11607459B1/en active Active
- 2022-12-28 US US18/147,070 patent/US11952384B2/en active Active
-
2023
- 2023-03-22 US US18/187,935 patent/US12434077B2/en active Active
- 2023-10-26 US US18/495,455 patent/US12091418B2/en active Active
- 2023-11-10 US US18/506,610 patent/US12168667B2/en active Active
-
2025
- 2025-08-04 US US19/289,628 patent/US20250367316A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7551056B2 (ja) | プログラマブルなポリマー薬物 | |
| Drewry et al. | Solid-phase synthesis of trisubstituted guanidines | |
| WO2019071153A1 (en) | PROGRAMMABLE DENDRITIC MEDICINES | |
| JP2024050717A (ja) | 生物学的に活性な化合物を含むイオン性ポリマー | |
| JP2021503450A (ja) | プログラム可能なポリマー薬 | |
| KR20200108866A (ko) | 생물학적 활성 화합물을 포함하는 강성 공간 군을 갖는 중합체 | |
| AU2013231819B2 (en) | Aminoacid lipids | |
| WO2019140128A1 (en) | Phosphoalkyl polymers comprising biologically active compounds | |
| JP7304128B2 (ja) | 白金耐性の克服における使用のためのテキサフィリン-白金(iv)コンジュゲート及び組成物 | |
| AU2022252848B2 (en) | Macrocyclic ligands with pendant chelating moieties and complexes thereof | |
| US8962838B2 (en) | Platinum complexes and their use | |
| JP2024537069A (ja) | ポリマーデュアル薬物の自動合成 | |
| JP2008517949A5 (cg-RX-API-DMAC7.html) | ||
| NL2020121B1 (en) | Platinum-based functional moieties for preparing cell targeting conjugates | |
| AU2018317611B2 (en) | Non-natural amatoxin-type antibody conjugate | |
| US20040142851A1 (en) | Hydrazinopeptoids and their uses for treating cancers | |
| CA2891593A1 (en) | Di-macrocycles | |
| CN105440059B (zh) | 氨基酸与邻菲啰啉或其衍生物的铜配合物及其制备方法和应用 | |
| AU2012350146A1 (en) | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals | |
| NL2020120B1 (en) | Methods for preparing cell targeting conjugates and conjugates obtainable by said methods | |
| CN104672213A (zh) | 一种具有抗肿瘤活性的酰胺类化合物及其应用 | |
| US12304920B2 (en) | Platinum complex, its preparation and therapeutic use | |
| KR101426872B1 (ko) | 금속 동위원소 표지를 위한 헤테로사이클릭 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 제조방법 | |
| TW202535475A (zh) | 包含喜樹鹼衍生物之抗c-Met抗體-藥物綴合物 | |
| KR20250168470A (ko) | 캄프토테신 유도체의 항체-약물 접합체 및 이의 용도 |